Meet Seth Rudnick

Venture Partner, Ace Clinical Strategist

Full Throttle, Flaps Down, Committed for Takeoff

Aviator Seth Rudnick joined Canaan 1998, and has been piloting our investments in biopharmaceutical and medical devices ever since. Seth led investments in several breakthrough healthcare companies including Chimerix (CRMX), a developer of antiviral therapies for immunocompromised patient populations; CombinatoRx, a pioneer in synergistic combination pharmaceuticals (CRXX); Esperion, therapies for the treatment of cardiovascular disease (acq. by Pfizer); Genaissance Pharmaceuticals, a pioneer in personalized medicine through population genomics (GNSC); Immunicon, a developer of proprietary cell- and molecular-based human diagnostic products (IMMC); and Pozen, therapeutic treatments of acute migraine (POZN). Seth currently sits on the boards of Abyrx, Liquidia Technologies, Pozen, SpineWave, VaxInnate, Square 1 Financial and Square 1 Bank. Seth was named to the Forbes Midas List twice.

Prior to Canaan, Seth served as CEO and Chairman of CytoTherapeutics (CTII), a developer of stem cell-based therapies to combat chronic diseases. Additionally, he helped start and headed R&D for Ortho Biotech, a division of Johnson & Johnson where he was instrumental in creating a portfolio of products that still generate significant Johnson & Johnson revenue today. He began his career at Schering-Plough and also directed pharmaceutical development efforts at Biogen.

Seth was a Yale Fellow in medical oncology where he was a Robert Wood Johnson Scholar. He received his medical training at Washington University Barnes Hospital. He earned his medical degree at the University of Virginia and holds a BA in history from the University of Pennsylvania. An Adjunct Clinical Professor of Medicine at University of North Carolina, Chapel Hill, he teaches and advises faculty members on biotechnology issues.